Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)

J. R. Chalmers, J. Schmitt, C. Apfelbacher, M. Dohil, L. F. Eichenfield, Eric Simpson, J. Singh, P. Spuls, K. S. Thomas, S. Admani, V. Aoki, M. Ardeleanu, S. Barbarot, T. Berger, J. N. Bergman, J. Block, N. Borok, T. Burton, S. L. Chamlin, S. DeckertC. C. Deklotz, L. B. Graff, Jon Hanifin, A. A. Hebert, R. Humphreys, N. Katoh, R. M. Kisa, D. J. Margolis, S. Merhand, R. Minnillo, H. Mizutani, H. Nankervis, Y. Ohya, P. Rodgers, M. E. Schram, J. F. Stalder, A. Svensson, R. Takaoka, A. Teper, W. L. Tom, L. Von Kobyletzki, E. Weisshaar, S. Zelt, H. C. Williams

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

This report provides a summary of the third meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in San Diego, CA, U.S.A., 6-7 April 2013 (HOME III). The meeting addressed the four domains that had previously been agreed should be measured in every eczema clinical trial: clinical signs, patient-reported symptoms, long-term control and quality of life. Formal presentations and nominal group techniques were used at this working meeting, attended by 56 voting participants (31 of whom were dermatologists). Significant progress was made on the domain of clinical signs. Without reference to any named scales, it was agreed that the intensity and extent of erythema, excoriation, oedema/papulation and lichenification should be included in the core outcome measure for the scale to have content validity. The group then discussed a systematic review of all scales measuring the clinical signs of eczema and their measurement properties, followed by a consensus vote on which scale to recommend for inclusion in the core outcome set. Research into the remaining three domains was presented, followed by discussions. The symptoms group and quality of life groups need to systematically identify all available tools and rate the quality of the tools. A definition of long-term control is needed before progress can be made towards recommending a core outcome measure. What's already known about this topic? Many different scales have been used to measure eczema, making it difficult to compare trials in meta-analyses and hampering improvements in clinical practice. HOME core outcome measures must pass the OMERACT (Outcome Measures in Rheumatology) filter of truth (validity), discrimination (sensitivity to change and responsiveness) and feasibility (ease of use, costs, time to perform and interpret). It has been previously agreed as part of the consensus process that four domains should be measured by the core outcomes: clinical signs, patient-reported symptoms, long-term control and health-related quality of life. What does this study add? Progress was made towards developing a core outcome set for measuring eczema in clinical trials. The group established the essential items to be included in the outcome measure for the clinical signs of eczema and was able to recommend a scale for the core set. The remaining three domains of patient-reported symptoms, long-term control and health-related quality of life require further work and meetings to determine the core outcome measures.

Original languageEnglish (US)
Pages (from-to)1318-1325
Number of pages8
JournalBritish Journal of Dermatology
Volume171
Issue number6
DOIs
StatePublished - Dec 1 2014

Fingerprint

Eczema
Atopic Dermatitis
Outcome Assessment (Health Care)
Clinical Trials
Quality of Life
Rheumatology
Politics
Erythema
Meta-Analysis
Edema
Costs and Cost Analysis

ASJC Scopus subject areas

  • Dermatology

Cite this

Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). / Chalmers, J. R.; Schmitt, J.; Apfelbacher, C.; Dohil, M.; Eichenfield, L. F.; Simpson, Eric; Singh, J.; Spuls, P.; Thomas, K. S.; Admani, S.; Aoki, V.; Ardeleanu, M.; Barbarot, S.; Berger, T.; Bergman, J. N.; Block, J.; Borok, N.; Burton, T.; Chamlin, S. L.; Deckert, S.; Deklotz, C. C.; Graff, L. B.; Hanifin, Jon; Hebert, A. A.; Humphreys, R.; Katoh, N.; Kisa, R. M.; Margolis, D. J.; Merhand, S.; Minnillo, R.; Mizutani, H.; Nankervis, H.; Ohya, Y.; Rodgers, P.; Schram, M. E.; Stalder, J. F.; Svensson, A.; Takaoka, R.; Teper, A.; Tom, W. L.; Von Kobyletzki, L.; Weisshaar, E.; Zelt, S.; Williams, H. C.

In: British Journal of Dermatology, Vol. 171, No. 6, 01.12.2014, p. 1318-1325.

Research output: Contribution to journalArticle

Chalmers, JR, Schmitt, J, Apfelbacher, C, Dohil, M, Eichenfield, LF, Simpson, E, Singh, J, Spuls, P, Thomas, KS, Admani, S, Aoki, V, Ardeleanu, M, Barbarot, S, Berger, T, Bergman, JN, Block, J, Borok, N, Burton, T, Chamlin, SL, Deckert, S, Deklotz, CC, Graff, LB, Hanifin, J, Hebert, AA, Humphreys, R, Katoh, N, Kisa, RM, Margolis, DJ, Merhand, S, Minnillo, R, Mizutani, H, Nankervis, H, Ohya, Y, Rodgers, P, Schram, ME, Stalder, JF, Svensson, A, Takaoka, R, Teper, A, Tom, WL, Von Kobyletzki, L, Weisshaar, E, Zelt, S & Williams, HC 2014, 'Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)', British Journal of Dermatology, vol. 171, no. 6, pp. 1318-1325. https://doi.org/10.1111/bjd.13237
Chalmers, J. R. ; Schmitt, J. ; Apfelbacher, C. ; Dohil, M. ; Eichenfield, L. F. ; Simpson, Eric ; Singh, J. ; Spuls, P. ; Thomas, K. S. ; Admani, S. ; Aoki, V. ; Ardeleanu, M. ; Barbarot, S. ; Berger, T. ; Bergman, J. N. ; Block, J. ; Borok, N. ; Burton, T. ; Chamlin, S. L. ; Deckert, S. ; Deklotz, C. C. ; Graff, L. B. ; Hanifin, Jon ; Hebert, A. A. ; Humphreys, R. ; Katoh, N. ; Kisa, R. M. ; Margolis, D. J. ; Merhand, S. ; Minnillo, R. ; Mizutani, H. ; Nankervis, H. ; Ohya, Y. ; Rodgers, P. ; Schram, M. E. ; Stalder, J. F. ; Svensson, A. ; Takaoka, R. ; Teper, A. ; Tom, W. L. ; Von Kobyletzki, L. ; Weisshaar, E. ; Zelt, S. ; Williams, H. C. / Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). In: British Journal of Dermatology. 2014 ; Vol. 171, No. 6. pp. 1318-1325.
@article{a9de3b90f0c943b78cc23f34d083859b,
title = "Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)",
abstract = "This report provides a summary of the third meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in San Diego, CA, U.S.A., 6-7 April 2013 (HOME III). The meeting addressed the four domains that had previously been agreed should be measured in every eczema clinical trial: clinical signs, patient-reported symptoms, long-term control and quality of life. Formal presentations and nominal group techniques were used at this working meeting, attended by 56 voting participants (31 of whom were dermatologists). Significant progress was made on the domain of clinical signs. Without reference to any named scales, it was agreed that the intensity and extent of erythema, excoriation, oedema/papulation and lichenification should be included in the core outcome measure for the scale to have content validity. The group then discussed a systematic review of all scales measuring the clinical signs of eczema and their measurement properties, followed by a consensus vote on which scale to recommend for inclusion in the core outcome set. Research into the remaining three domains was presented, followed by discussions. The symptoms group and quality of life groups need to systematically identify all available tools and rate the quality of the tools. A definition of long-term control is needed before progress can be made towards recommending a core outcome measure. What's already known about this topic? Many different scales have been used to measure eczema, making it difficult to compare trials in meta-analyses and hampering improvements in clinical practice. HOME core outcome measures must pass the OMERACT (Outcome Measures in Rheumatology) filter of truth (validity), discrimination (sensitivity to change and responsiveness) and feasibility (ease of use, costs, time to perform and interpret). It has been previously agreed as part of the consensus process that four domains should be measured by the core outcomes: clinical signs, patient-reported symptoms, long-term control and health-related quality of life. What does this study add? Progress was made towards developing a core outcome set for measuring eczema in clinical trials. The group established the essential items to be included in the outcome measure for the clinical signs of eczema and was able to recommend a scale for the core set. The remaining three domains of patient-reported symptoms, long-term control and health-related quality of life require further work and meetings to determine the core outcome measures.",
author = "Chalmers, {J. R.} and J. Schmitt and C. Apfelbacher and M. Dohil and Eichenfield, {L. F.} and Eric Simpson and J. Singh and P. Spuls and Thomas, {K. S.} and S. Admani and V. Aoki and M. Ardeleanu and S. Barbarot and T. Berger and Bergman, {J. N.} and J. Block and N. Borok and T. Burton and Chamlin, {S. L.} and S. Deckert and Deklotz, {C. C.} and Graff, {L. B.} and Jon Hanifin and Hebert, {A. A.} and R. Humphreys and N. Katoh and Kisa, {R. M.} and Margolis, {D. J.} and S. Merhand and R. Minnillo and H. Mizutani and H. Nankervis and Y. Ohya and P. Rodgers and Schram, {M. E.} and Stalder, {J. F.} and A. Svensson and R. Takaoka and A. Teper and Tom, {W. L.} and {Von Kobyletzki}, L. and E. Weisshaar and S. Zelt and Williams, {H. C.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1111/bjd.13237",
language = "English (US)",
volume = "171",
pages = "1318--1325",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)

AU - Chalmers, J. R.

AU - Schmitt, J.

AU - Apfelbacher, C.

AU - Dohil, M.

AU - Eichenfield, L. F.

AU - Simpson, Eric

AU - Singh, J.

AU - Spuls, P.

AU - Thomas, K. S.

AU - Admani, S.

AU - Aoki, V.

AU - Ardeleanu, M.

AU - Barbarot, S.

AU - Berger, T.

AU - Bergman, J. N.

AU - Block, J.

AU - Borok, N.

AU - Burton, T.

AU - Chamlin, S. L.

AU - Deckert, S.

AU - Deklotz, C. C.

AU - Graff, L. B.

AU - Hanifin, Jon

AU - Hebert, A. A.

AU - Humphreys, R.

AU - Katoh, N.

AU - Kisa, R. M.

AU - Margolis, D. J.

AU - Merhand, S.

AU - Minnillo, R.

AU - Mizutani, H.

AU - Nankervis, H.

AU - Ohya, Y.

AU - Rodgers, P.

AU - Schram, M. E.

AU - Stalder, J. F.

AU - Svensson, A.

AU - Takaoka, R.

AU - Teper, A.

AU - Tom, W. L.

AU - Von Kobyletzki, L.

AU - Weisshaar, E.

AU - Zelt, S.

AU - Williams, H. C.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - This report provides a summary of the third meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in San Diego, CA, U.S.A., 6-7 April 2013 (HOME III). The meeting addressed the four domains that had previously been agreed should be measured in every eczema clinical trial: clinical signs, patient-reported symptoms, long-term control and quality of life. Formal presentations and nominal group techniques were used at this working meeting, attended by 56 voting participants (31 of whom were dermatologists). Significant progress was made on the domain of clinical signs. Without reference to any named scales, it was agreed that the intensity and extent of erythema, excoriation, oedema/papulation and lichenification should be included in the core outcome measure for the scale to have content validity. The group then discussed a systematic review of all scales measuring the clinical signs of eczema and their measurement properties, followed by a consensus vote on which scale to recommend for inclusion in the core outcome set. Research into the remaining three domains was presented, followed by discussions. The symptoms group and quality of life groups need to systematically identify all available tools and rate the quality of the tools. A definition of long-term control is needed before progress can be made towards recommending a core outcome measure. What's already known about this topic? Many different scales have been used to measure eczema, making it difficult to compare trials in meta-analyses and hampering improvements in clinical practice. HOME core outcome measures must pass the OMERACT (Outcome Measures in Rheumatology) filter of truth (validity), discrimination (sensitivity to change and responsiveness) and feasibility (ease of use, costs, time to perform and interpret). It has been previously agreed as part of the consensus process that four domains should be measured by the core outcomes: clinical signs, patient-reported symptoms, long-term control and health-related quality of life. What does this study add? Progress was made towards developing a core outcome set for measuring eczema in clinical trials. The group established the essential items to be included in the outcome measure for the clinical signs of eczema and was able to recommend a scale for the core set. The remaining three domains of patient-reported symptoms, long-term control and health-related quality of life require further work and meetings to determine the core outcome measures.

AB - This report provides a summary of the third meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in San Diego, CA, U.S.A., 6-7 April 2013 (HOME III). The meeting addressed the four domains that had previously been agreed should be measured in every eczema clinical trial: clinical signs, patient-reported symptoms, long-term control and quality of life. Formal presentations and nominal group techniques were used at this working meeting, attended by 56 voting participants (31 of whom were dermatologists). Significant progress was made on the domain of clinical signs. Without reference to any named scales, it was agreed that the intensity and extent of erythema, excoriation, oedema/papulation and lichenification should be included in the core outcome measure for the scale to have content validity. The group then discussed a systematic review of all scales measuring the clinical signs of eczema and their measurement properties, followed by a consensus vote on which scale to recommend for inclusion in the core outcome set. Research into the remaining three domains was presented, followed by discussions. The symptoms group and quality of life groups need to systematically identify all available tools and rate the quality of the tools. A definition of long-term control is needed before progress can be made towards recommending a core outcome measure. What's already known about this topic? Many different scales have been used to measure eczema, making it difficult to compare trials in meta-analyses and hampering improvements in clinical practice. HOME core outcome measures must pass the OMERACT (Outcome Measures in Rheumatology) filter of truth (validity), discrimination (sensitivity to change and responsiveness) and feasibility (ease of use, costs, time to perform and interpret). It has been previously agreed as part of the consensus process that four domains should be measured by the core outcomes: clinical signs, patient-reported symptoms, long-term control and health-related quality of life. What does this study add? Progress was made towards developing a core outcome set for measuring eczema in clinical trials. The group established the essential items to be included in the outcome measure for the clinical signs of eczema and was able to recommend a scale for the core set. The remaining three domains of patient-reported symptoms, long-term control and health-related quality of life require further work and meetings to determine the core outcome measures.

UR - http://www.scopus.com/inward/record.url?scp=84908096132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908096132&partnerID=8YFLogxK

U2 - 10.1111/bjd.13237

DO - 10.1111/bjd.13237

M3 - Article

C2 - 24980543

AN - SCOPUS:84908096132

VL - 171

SP - 1318

EP - 1325

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 6

ER -